Luminopia announced preliminary results from a pilot study evaluating its prescription digital therapeutic in children with intermittent exotropia (IXT), a condition characterized by the outward drifting of one eye. The study, led by Evan Silverstein, MD, Associate Professor at Virginia Commonwealth University School of Medicine, explored whether Luminopia’s binocular (dichoptic) therapy could improve eye alignment control in young patients. Intermittent exotropia is a common yet challenging pediatric vision disorder that often requires long-term management and, in some cases, surgery. The pilot study included 10 children between the ages of 4 and 7 diagnosed with unilateral IXT. Participants were prescribed 1 hour of Luminopia therapy per day, 6 days a week, with all achieving at least 50% adherence. Researchers assessed distance control scores and stereopsis (depth perception) at baseline, after 3 months of treatment, and again following a 3-month washout period. Results showed a statistically significant improvement in distance control scores, which decreased from an average of 2.9 at baseline to 1.7 after 3 months (P=0.01). Notably, these improvements were sustained at the 6-month mark, even after discontinuation of therapy, suggesting a lasting benefit. The study also observed a trend toward improved stereoacuity, though further research is needed to confirm this finding. “While this is a small pilot, these findings are exciting because they suggest that dichoptic therapy delivered via Luminopia may improve control in children with IXT,” said Dr. Silverstein. “This lays the groundwork for Luminopia to potentially become the first non-surgical, FDA-cleared treatment for IXT.” Luminopia’s approach uses digital content delivered through specialized hardware to stimulate both eyes simultaneously, encouraging the brain to process visual input more effectively—a method designed to address the neurological basis of certain vision disorders. “This pilot study offers promising early data and underscores the potential of dichoptic therapy to transform care for children with intermittent exotropia,” said Scott Xiao, founder and CEO of Luminopia. “The findings also validate the broader therapeutic potential of our platform in treating conditions at the intersection of the visual system and the brain.”